BioTelemetry, Inc. (NASDAQ:BEAT) has received a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $43.50.
BEAT has been the topic of a number of research reports. Raymond James Financial initiated coverage on shares of BioTelemetry in a research report on Thursday, October 26th. They set an “outperform” rating and a $37.00 target price on the stock. SunTrust Banks assumed coverage on shares of BioTelemetry in a research report on Monday, October 23rd. They set a “buy” rating and a $41.00 target price on the stock. Zacks Investment Research downgraded shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 2nd. Dougherty & Co reiterated a “buy” rating and issued a $40.00 price target on shares of BioTelemetry in a research report on Wednesday, November 8th. Finally, BidaskClub upgraded shares of BioTelemetry from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th.
Large investors have recently made changes to their positions in the stock. Winslow Evans & Crocker Inc. acquired a new stake in shares of BioTelemetry in the 3rd quarter valued at approximately $109,000. First Dallas Securities Inc. bought a new stake in BioTelemetry during the 4th quarter worth approximately $133,000. Piedmont Investment Advisors LLC bought a new stake in BioTelemetry during the 2nd quarter worth approximately $207,000. UBS Asset Management Americas Inc. bought a new stake in BioTelemetry during the 2nd quarter worth approximately $208,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in BioTelemetry during the 2nd quarter worth approximately $212,000. Institutional investors and hedge funds own 83.27% of the company’s stock.
BioTelemetry (NASDAQ BEAT) traded up $0.90 during trading on Tuesday, reaching $32.55. 284,500 shares of the company’s stock were exchanged, compared to its average volume of 418,293. The company has a current ratio of 1.60, a quick ratio of 1.48 and a debt-to-equity ratio of 0.75. BioTelemetry has a 52 week low of $23.30 and a 52 week high of $39.20. The firm has a market cap of $1,025.72, a P/E ratio of 25.23, a PEG ratio of 1.41 and a beta of 0.67.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2018/02/13/biotelemetry-inc-beat-given-consensus-recommendation-of-hold-by-brokerages.html.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.